scispace - formally typeset
C

Christopher P Cheyne

Researcher at University of Liverpool

Publications -  32
Citations -  1151

Christopher P Cheyne is an academic researcher from University of Liverpool. The author has contributed to research in topics: Population & Medicine. The author has an hindex of 11, co-authored 25 publications receiving 713 citations.

Papers
More filters
Journal ArticleDOI

The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs

TL;DR: An accumulation of evidence demonstrates that the risks associated with prenatal sodium VPA exposure include an increased prevalence of neurodevelopmental disorders, whether such disorders are discrete or represent the severe end of a continuum of altered neuro developmental functioning requires further investigation.
Journal ArticleDOI

IQ at 6 years after in utero exposure to antiepileptic drugs: A controlled cohort study

TL;DR: For example, this article found that children exposed to high-dose valproate had an 8-fold increased need for educational intervention relative to control children (adjusted relative risk, 95% CI 8.0, 2.5-19.7; p p p = 0.04) and a 6-fold increase in educational intervention (95% CI 1.4-18.0; p =0.01).
Journal ArticleDOI

High incidence and prevalence of visual problems after acute stroke: An epidemiology study with implications for service delivery.

TL;DR: Incidence and point prevalence of visual problems in acute stroke is alarmingly high, affecting over half the survivors, and crucial information can be provided on visual status and its functional significance to the stroke team, patients and carers, enabling early intervention.
Journal ArticleDOI

In utero exposure to levetiracetam vs valproate: development and language at 3 years of age.

TL;DR: Children exposed to LEV in utero were superior in their language and motor development in comparison to children exposed to VPA, and this information should be used collaboratively between health care professionals and WWE when deciding on women's preferred choice of antiepileptic drug.